The effectiveness of EGFR (epidermal growth factor receptor) and VEGFR (vascular endothelial growth factor receptor) inhibitors faces limitations in KRAS wild-type colorectal carcinoma (CRC). Here, EGFR is linked to colorectal carcinoma.